Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
17.43
+0.27 (+1.57%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
Next >
Teva Announces Changes to Executive Management Team
September 28, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
September 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
September 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Settles Price Fixing Charges With U.S. DOJ
August 21, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports Second Quarter 2023 Financial Results
August 02, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
July 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 24, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
July 24, 2023
From
Alvotech
Via
GlobeNewswire
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
July 05, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
June 30, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
June 15, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims
June 12, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023
From
Alvotech
Via
GlobeNewswire
Teva Concludes Nationwide Opioids Settlement Agreement
June 08, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management
June 06, 2023
From
Phil Inc.
Via
Business Wire
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
June 02, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
May 20, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Launches New “Pivot to Growth” Strategy
May 18, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.
May 15, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
May 10, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule
May 09, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
U.S. Mental Health Access Program Expands Medicine Donation to Seven New States
May 03, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
April 28, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Launch New Growth Strategy at Investor Day
April 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
April 14, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Complete Response Letter Received for AVT02 Biologics License Application
April 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
April 11, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System
March 27, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
March 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.